Some Blue Cross and Blue Shield insurers dipped their toes into expanding coverage for blockbuster weight-loss drugs, then ...

Fifteen Connecticut companies made the 2025 Fortune 500 list of the largest U.S. corporations, which was announced Monday-- a sign of stability in the state's corporate sector. Bloomfield- ...

Are you weening yourself off a compounded version of the drug? Considering switching insurers in order to keep your ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Drugmakers are introducing discounts and lower-cost options for consumers who have to pay for GLP-1 drugs out of pocket. News outlets look at the trend in pricing for drugs like Wegovy and Zepbound.

Blue Cross plans are retreating from GLP-1 weight-loss drug coverage after spending hundreds of millions of dollars on the ...

Cigna's Evernorth business caps GLP-1 drug copays at $200 or less, aiming to boost affordability for patients and cut costs ...

Here are four payer-related headlines in the last two weeks for ASCs to know. 1. Medical practices and hospitals saw claims denials increase and prior authorization denials decrease in 2024, according ...

The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit insured customers’ monthly out-of-pocket expenses for weight-loss drugs Zepbound ...

The Cigna Group (NYSE:CI)’s Evernorth division ... monthly out-of-pocket expenses for weight-loss drugs Zepbound and Wegovy to $200. Beginning in the second half of 2025, the program targets ...

Cigna has announced a deal to cap client copays on popular GLP-1 weight loss drugs by Eli Lilly and Novo Nordisk at $200 per month, a sum that would count toward a patient's deductible. Currently only ...